Counterpoint Mutual Funds LLC bought a new stake in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 34,086 shares of the company's stock, valued at approximately $1,820,000. Doximity comprises about 0.2% of Counterpoint Mutual Funds LLC's portfolio, making the stock its 20th biggest holding.
A number of other hedge funds have also made changes to their positions in DOCS. Corient Private Wealth LLC raised its stake in Doximity by 3.9% in the 4th quarter. Corient Private Wealth LLC now owns 8,887 shares of the company's stock valued at $474,000 after purchasing an additional 334 shares during the last quarter. one8zero8 LLC purchased a new position in shares of Doximity in the fourth quarter worth about $267,000. Natixis Advisors LLC lifted its stake in shares of Doximity by 12.8% in the fourth quarter. Natixis Advisors LLC now owns 35,882 shares of the company's stock worth $1,916,000 after buying an additional 4,067 shares in the last quarter. Swiss National Bank boosted its position in Doximity by 2.5% during the fourth quarter. Swiss National Bank now owns 221,600 shares of the company's stock worth $11,831,000 after acquiring an additional 5,400 shares during the last quarter. Finally, Rakuten Securities Inc. grew its stake in Doximity by 696.2% during the 4th quarter. Rakuten Securities Inc. now owns 18,393 shares of the company's stock valued at $982,000 after acquiring an additional 16,083 shares in the last quarter. Institutional investors and hedge funds own 87.19% of the company's stock.
Insider Buying and Selling
In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now owns 6,360 shares of the company's stock, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 37.40% of the company's stock.
Analysts Set New Price Targets
DOCS has been the topic of several recent research reports. JPMorgan Chase & Co. boosted their target price on Doximity from $30.00 to $48.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Canaccord Genuity Group upped their target price on Doximity from $60.00 to $71.00 and gave the company a "hold" rating in a report on Friday, February 7th. Raymond James reissued an "outperform" rating and set a $83.00 price target (up previously from $65.00) on shares of Doximity in a research report on Friday, February 7th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Doximity in a research note on Friday, February 7th. Finally, Leerink Partners raised shares of Doximity from a "market perform" rating to an "outperform" rating and increased their price target for the company from $60.00 to $90.00 in a research note on Friday, February 7th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $64.22.
View Our Latest Stock Analysis on Doximity
Doximity Stock Performance
DOCS stock traded up $0.24 during mid-day trading on Friday, reaching $63.01. The company had a trading volume of 4,032,344 shares, compared to its average volume of 1,880,534. The firm has a fifty day simple moving average of $64.20 and a 200 day simple moving average of $53.21. The company has a market capitalization of $11.76 billion, a price-to-earnings ratio of 63.01, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a fifty-two week low of $22.96 and a fifty-two week high of $85.21.
About Doximity
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Further Reading
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
